{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:56:53Z","timestamp":1771869413508,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014384","name":"Amarin Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014384","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ajpc.2025.101387","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T08:07:59Z","timestamp":1766131679000},"page":"101387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1679-2095","authenticated-orcid":false,"given":"Michael","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliot A.","family":"Brinton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ph. Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven B.","family":"Ketchum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando Lira","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpc.2025.101387_bib0001","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2025.101387_bib0002","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1001\/jama.288.21.2709","article-title":"The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men","volume":"288","author":"Lakka","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ajpc.2025.101387_bib0003","series-title":"A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association.Circulation","first-page":"1636","volume":"148","author":"Ndumele","year":"2023"},{"key":"10.1016\/j.ajpc.2025.101387_bib0004","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.2174\/1871530323666230309144825","article-title":"Metabolic syndrome: the constellation of Co-morbidities, a global threat","volume":"23","author":"Madan","year":"2023","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.ajpc.2025.101387_bib0005","doi-asserted-by":"crossref","first-page":"465","DOI":"10.4103\/1735-1995.163969","article-title":"Metabolic syndrome and its components associated with chronic kidney disease","volume":"20","author":"Maleki","year":"2015","journal-title":"J Res Med Sci"},{"key":"10.1016\/j.ajpc.2025.101387_bib0006","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.055560","article-title":"Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: REDUCE-IT RENAL","volume":"144","author":"Majithia","year":"2021","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101387_bib0007","doi-asserted-by":"crossref","first-page":"oead114","DOI":"10.1093\/ehjopen\/oead114","article-title":"Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn","volume":"3","author":"Miller","year":"2023","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.ajpc.2025.101387_bib0008","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"REDUCE-IT investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2025.101387_bib0009","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"REDUCE-IT investigators. Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ajpc.2025.101387_bib0010","first-page":"ehaf314","article-title":"European Atherosclerosis Society Consensus. Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement","author":"Romeo","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajpc.2025.101387_bib0011","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jama.2010.1322","article-title":"Steg PG; REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis","volume":"304","author":"Bhatt","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ajpc.2025.101387_bib0012","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020377","article-title":"Triglyceride levels and residual risk of atherosclerotic cardiovascular disease events and death in adults receiving statin therapy for primary or secondary prevention: insights from the KP REACH study","volume":"10","author":"Ambrosy","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2025.101387_bib0013","first-page":"2292","volume":"123","author":"Miller","year":"2011"},{"key":"10.1016\/j.ajpc.2025.101387_bib0014","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.jacc.2019.06.043","article-title":"REDUCE-IT investigators. Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles","volume":"74","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2025.101387_bib0015","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.119.313286","article-title":"Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid","volume":"40","author":"Mason","year":"2020","journal-title":"Arter Thromb Vasc Biol"},{"key":"10.1016\/j.ajpc.2025.101387_bib0016","article-title":"Metabolic syndrome-related kidney injury: a review and update","volume":"13","author":"Lin","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ajpc.2025.101387_bib0017","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13649","article-title":"Association of metabolic syndrome and chronic kidney disease","volume":"25","author":"Scurt","year":"2024","journal-title":"Obes Rev"},{"key":"10.1016\/j.ajpc.2025.101387_bib0018","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41392-022-01036-5","article-title":"Signaling pathways of chronic kidney diseases, implications for therapeutics","volume":"7","author":"Yuan","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101387_bib0019","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/ehjcvp\/pvaa118","article-title":"REDUCE-IT investigators. REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results","volume":"7","author":"Olshansky","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101387_bib0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCULATIONAHA.120.050276","article-title":"Ballantyne CM; REDUCE-IT investigators. Reduction in revascularization with icosapent ethyl: insights from REDUCE-IT revascularization analyses","volume":"143","author":"Peterson","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2025.101387_bib0021","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.jacc.2022.02.035","article-title":"REDUCE-IT investigators. Prevention of cardiovascular events and mortality with icosapent ethyl in patients with prior myocardial infarction","volume":"79","author":"Gaba","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2025.101387_bib0022","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022937","article-title":"REDUCE-IT Investigators. Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention: insights from REDUCE-IT PCI","volume":"11","author":"Peterson","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2025.101387_bib0023","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1161\/CIRCULATIONAHA.121.056290","article-title":"REDUCE-IT investigators. Icosapent ethyl reduces ischemic events in patients with a history of previous coronary artery bypass grafting: REDUCE-IT CABG","volume":"144","author":"Verma","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2025.101387_bib0024","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurheartj\/ehad889","article-title":"Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial","volume":"45","author":"Sayah","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajpc.2025.101387_bib0025","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024999","article-title":"REDUCE-IT investigators. Impact of icosapent ethyl on cardiovascular risk reduction in patients with heart failure in REDUCE-IT","volume":"11","author":"Selvaraj","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2025.101387_bib0026","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ehjcvp\/pvac045","article-title":"Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking","volume":"9","author":"Miller","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.ajpc.2025.101387_bib0027","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jacc.2024.02.016","article-title":"Lipoprotein(a) blood levels and cardiovascular risk reduction with icosapent ethyl","volume":"83","author":"Szarek","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667725004623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667725004623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:56:49Z","timestamp":1771865809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667725004623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":27,"alternative-id":["S2666667725004623"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2025.101387","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2025.101387","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101387"}}